文献速递腹部CT

基于CT的影像组学特征能否预测结直肠癌的KRAS/NRAS/BRAF突变

Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
PubMed 文献 · Eur Radiol · 2018-01-15

本回顾性研究纳入病理确诊的结直肠癌患者,原发队列61例、验证队列56例,治疗前接受KRAS/NRAS/BRAF突变检测和增强CT,从门静脉期全肿瘤图像提取346个影像组学特征,用RELIEFF和支持向量机构建影像组学特征。该特征与KRAS/NRAS/BRAF突变显著相关(P < 0.001),原发队列和验证队列预测突变的AUC分别为0.869和0.829。临床背景、肿瘤分期和组织学分化在两个队列中均与突变无关联(P>0.05)。

要点

  • 基于门静脉期CT全肿瘤提取的影像组学特征与结直肠癌KRAS/NRAS/BRAF突变显著相关(P < 0.001)。
  • 原发队列预测突变的AUC 0.869、敏感度0.757、特异度0.833;验证队列AUC 0.829、敏感度0.686、特异度0.857。
  • 临床背景、肿瘤分期和组织学分化在两个队列中均不能预测KRAS/NRAS/BRAF突变(P>0.05)。

核心结论

  • 所提出的基于CT的影像组学特征与KRAS/NRAS/BRAF突变相关,CT可能有助于分析结直肠癌的肿瘤基因型,从而有助于确定治疗策略。

研究设计与样本

  • 回顾性研究,原发队列61例、验证队列56例,均为病理确诊的结直肠癌患者,治疗前接受KRAS/NRAS/BRAF突变检测和增强CT,从门静脉期CT全肿瘤图像提取346个影像组学特征,采用RELIEFF和支持向量机方法筛选关键特征并构建影像组学特征。

关键影像表现/征象

  • 影像组学特征从门静脉期CT图像上的整个原发肿瘤提取,共346个特征。
  • 影像组学特征与KRAS/NRAS/BRAF突变显著相关(P < 0.001)。

诊断标准与关键数值

  • 原发队列预测KRAS/NRAS/BRAF突变的AUC为0.869,敏感度为0.757,特异度为0.833。
  • 验证队列预测KRAS/NRAS/BRAF突变的AUC为0.829,敏感度为0.686,特异度为0.857。

临床应用与阅片要点

  • 作者认为CT可能有助于分析结直肠癌的肿瘤基因型,从而有助于确定治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate whether CT-based radiomics signature can predict KRAS/NRAS/BRAF mutations in colorectal cancer (CRC).

METHODS: This retrospective study consisted of a primary cohort (n = 61) and a validation cohort (n = 56) with pathologically confirmed CRC. Patients underwent KRAS/NRAS/BRAF mutation tests and contrast-enhanced CT before treatment. A total of 346 radiomics features were extracted from portal venous-phase CT images of the entire primary tumour. Associations between the genetic mutations and clinical background, tumour staging, and histological differentiation were assessed using univariate analysis. RELIEFF and support vector machine methods were performed to select key features and build a radiomics signature.

RESULTS: The radiomics signature was significantly associated with KRAS/NRAS/BRAF mutations (P < 0.001). The area under the curve, sensitivity, and specificity for predicting KRAS/NRAS/BRAF mutations were 0.869, 0.757, and 0.833 in the primary cohort, respectively, while they were 0.829, 0.686, and 0.857 in the validation cohort, respectively. Clinical background, tumour staging, and histological differentiation were not associated with KRAS/NRAS/BRAF mutations in both cohorts (P>0.05).

CONCLUSIONS: The proposed CT-based radiomics signature is associated with KRAS/NRAS/BRAF mutations. CT may be useful for analysis of tumour genotype in CRC and thus helpful to determine therapeutic strategies.

KEY POINTS: • Key features were extracted from CT images of the primary colorectal tumour. • The proposed radiomics signature was significantly associated with KRAS/NRAS/BRAF mutations. • In the primary cohort, the proposed radiomics signature predicted mutations. • Clinical background, tumour staging, and histological differentiation were unable to predict mutations.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yang L, Dong D, Fang M, et al. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? Eur Radiol. 2018. PMID: 29335867. doi:10.1007/s00330-017-5146-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。